[{"orgOrder":0,"company":"Mundipharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Rezafungin","moa":"Candida","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mundipharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Mundipharma \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Moxifloxacin","moa":"Bacterial DNA gyrase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"Bacterial DNA gyrase | Topoisomerase IV","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Curetis","sponsor":"BioVersys AG","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Antibiotic","year":"2022","type":"Collaboration","leadProduct":"Rifabutin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Curetis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Curetis \/ BioVersys AG","highestDevelopmentStatusID":"6","companyTruncated":"Curetis \/ BioVersys AG"},{"orgOrder":0,"company":"CureVac","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"mRNA Vaccine","moa":"CD4 T-cell","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CureVac \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CureVac \/ Undisclosed"},{"orgOrder":0,"company":"Evotec","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"EVT894","moa":"Chikungunya viral protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Evotec \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Evotec \/ National Institutes of Health"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Emodepside","moa":"Gqalpha protein\/Phospholipase-Cbeta","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Innovative Molecules","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"IM-250","moa":"Helicase-primase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Innovative Molecules","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovative Molecules \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovative Molecules \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Deleobuvir","moa":"Hepatitis C virus NS5B RNA-dependent RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Faldaprevir","moa":"Hepatitis C virus serine protease, NS3\/NS4A","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"BI224436","moa":"HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Ratiopharm GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Nevirapine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ratiopharm GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ratiopharm GmbH \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ratiopharm GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Tenofovir","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Atriva Therapeutics","sponsor":"SGS Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"zapnometinib","moa":"MAP2K||MEK receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Atriva Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Atriva Therapeutics \/ SGS Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Atriva Therapeutics \/ SGS Life Sciences"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Hormone","year":"2012","type":"Inapplicable","leadProduct":"Levonorgestrel","moa":"Progesterone receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"CureVac","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Oligonucleotide","year":"2014","type":"Inapplicable","leadProduct":"CV8102","moa":"Retinoic acid-inducible gene-1 (RIG-1)","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CureVac \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CureVac \/ Undisclosed"},{"orgOrder":0,"company":"BioNTech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"BNT165b1","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioNTech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BioNTech \/ Undisclosed"},{"orgOrder":0,"company":"CureVac","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2023","type":"Public Offering","leadProduct":"CV0501","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CureVac","amount2":0.25,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.25,"dosageForm":"Injection","sponsorNew":"CureVac \/ Goldman Sachs & Co","highestDevelopmentStatusID":"6","companyTruncated":"CureVac \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"CureVac","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2023","type":"Public Offering","leadProduct":"CV0501","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CureVac","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.25,"dosageForm":"Injection","sponsorNew":"CureVac \/ Goldman Sachs & Co","highestDevelopmentStatusID":"6","companyTruncated":"CureVac \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"CureVac","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"CV0501","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CureVac \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CureVac \/ Undisclosed"},{"orgOrder":0,"company":"CureVac","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"CV0501","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CureVac \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CureVac \/ Undisclosed"},{"orgOrder":0,"company":"CureVac","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"CV0501","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CureVac \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CureVac \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Riociguat","moa":"Soluble guanylate cyclase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"BioNTech","sponsor":"Fosun Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"BNT162b1","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioNTech \/ Fosun Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"BioNTech \/ Fosun Pharmaceutical"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Tolbutamide","moa":"Sulfonylurea receptor 1, Kir6.2","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"AiCuris","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"AIC468","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"AiCuris","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AiCuris \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AiCuris \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"BAY3389934","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"BioNTech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"BNT163","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioNTech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BioNTech \/ Undisclosed"},{"orgOrder":0,"company":"BioNTech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"BNT163","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioNTech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BioNTech \/ Undisclosed"},{"orgOrder":0,"company":"BioNTech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"BNT165","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioNTech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BioNTech \/ Undisclosed"},{"orgOrder":0,"company":"BioNTech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"BNT165","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioNTech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BioNTech \/ Undisclosed"},{"orgOrder":0,"company":"BioNTech","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2023","type":"Partnership","leadProduct":"BNT166","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"BioNTech","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.089999999999999997,"dosageForm":"Injection","sponsorNew":"BioNTech \/ CEPI","highestDevelopmentStatusID":"6","companyTruncated":"BioNTech \/ CEPI"},{"orgOrder":0,"company":"BioNTech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"BNT331","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Insert","sponsorNew":"BioNTech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BioNTech \/ Undisclosed"},{"orgOrder":0,"company":"CureVac","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"CV7201","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CureVac \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CureVac \/ Undisclosed"},{"orgOrder":0,"company":"CureVac","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"CV7202","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CureVac \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CureVac \/ Undisclosed"},{"orgOrder":0,"company":"CureVac","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Cvsqiv","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CureVac \/ GSK","highestDevelopmentStatusID":"6","companyTruncated":"CureVac \/ GSK"},{"orgOrder":0,"company":"Nova","sponsor":"Mercia Pharma | Nova Laboratories | The Emmes Company, LLC","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"MER4101","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Nova","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nova \/ Mercia Pharma | Nova Laboratories | The Emmes Company, LLC","highestDevelopmentStatusID":"6","companyTruncated":"Nova \/ Mercia Pharma | Nova Laboratories | The Emmes Company, LLC"},{"orgOrder":0,"company":"IDT Biologika GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"MVA-SARS-2-S Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"IDT Biologika GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IDT Biologika GmbH \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"IDT Biologika GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Nova","sponsor":"Cetero Research | US Department of Defense","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2011","type":"Inapplicable","leadProduct":"NDV-3 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Nova","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nova \/ Cetero Research | US Department of Defense","highestDevelopmentStatusID":"6","companyTruncated":"Nova \/ Cetero Research | US Department of Defense"},{"orgOrder":0,"company":"Nova","sponsor":"US Department of Defense","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2011","type":"Inapplicable","leadProduct":"NDV-3 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Nova","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nova \/ US Department of Defense","highestDevelopmentStatusID":"6","companyTruncated":"Nova \/ US Department of Defense"},{"orgOrder":0,"company":"Medigene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Plant Extract\/Herbal","year":"2011","type":"Inapplicable","leadProduct":"Sinecatechin","moa":"Immune||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Medigene \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Medigene \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"BAY 3389934","moa":"Factor Xa\/Thrombin","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bayer AG \/ Undisclosed"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
